Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 25Lymphoma 21Neutropenia 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Carcinoma, Non-Small-Cell Lung 8Multiple Myeloma 7Leukemia 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Urinary Bladder Neoplasms 4Testicular Neoplasms 4Sarcoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Hodgkin Disease 4Central Nervous System Neoplasms 4Testicular Germ Cell Tumor 3Teratoma 3Rhabdomyosarcoma 3Chemotherapy-induced Neutropenia 3Carcinoma, Ovarian Epithelial 3Carcinoma, Embryonal 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

Rituximab 45Cyclophosphamide 34Doxorubicin 16fludarabine 14Prednisone 14Vincristine 13Etoposide 13ibrutinib 10Mycophenolic Acid 8Bortezomib 8Magnetic Resonance Spectroscopy 7Lenalidomide 7Cytarabine 7pembrolizumab 6Immunotherapy, Adoptive 6polatuzumab vedotin 5fludarabine phosphate 5Whole-Body Irradiation 5Vorinostat 5Tacrolimus 5Specimen Handling 5CT-P10 5obinutuzumab 4ibritumomab tiuxetan 4Nivolumab 4Ifosfamide 4Carmustine 4Carboplatin 4Antilymphocyte Serum 4tafasitamab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell × pegfilgrastim × Clear all
NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡